HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

Angelo Di Leo, Denis Larsimont, Virginie Durbecq et al.|Breast Cancer Research and Treatment|2004

Cited by 138